Effective March 27, 2023, the National Quality Forum (NQF) is no longer the consensus-based entity (CBE) funded through the Centers for Medicare & Medicaid Services (CMS) National Consensus Development and Strategic Planning for Health Care Quality Measurement Contract. Battelle has been selected to oversee the endorsement & maintenance (E&M) of clinical quality and cost/resource use measures. Since the Fall 2022 cycle launched at NQF, measures submitted to this E&M cycle continued along the prior E&M protocols that were in place at time of the Fall 2022 “Intent to Submit.” Battelle took over the E&M work for the Fall 2022 cycle after developers and/or stewards submitted their full measure information to NQF, which for CBE #3713e, the most recent measure specifications can be found here: https://p4qm.org/sites/default/files/2024-02/3713e.zip
Battelle took over the E&M work beginning with the public comment period to close the E&M committees for the post-comment meeting, convening the CSAC to render a final endorsement decision, and executing the appeals period.
Measure Specs
General Information
Numerator
Inpatient hospitalizations for patients who develop acute kidney injury (AKI) (stage 2 or greater) during the encounter, as evidenced by: • A subsequent increase in serum creatinine value at least 2 times higher than the lowest serum creatinine value, and the increased value is greaterthan the highest sex-specific normal value for serum creatinine; or • Kidney dialysis (continuous renal replacement therapy (CRRT), hemodialysis or peritoneal dialysis) initiated 48 hours or more after the start of theencounter.
Denominator
Inpatient hospitalizations for patients 18 years of age or older at the start if the encounter without a diagnosis of obstetrics, with a length of stay of 48 hours or longer who had at least one serum creatinine value after 48 hours from the start of the encounter.
Measure Record
Point of Contact
United States
United States
Public Comments